tiprankstipranks
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HK:2563)
:2563
Hong Kong Market
Want to see HK:2563 full AI Analyst Report?

Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Financial Statements

0 Followers

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Financial Overview

Beijing Biostar Pharmaceuticals Co., Ltd. Class H's market cap is currently HK$1.68B. The company's EPS TTM is HK$-0.3436; its P/E ratio is -12.51; Beijing Biostar Pharmaceuticals Co., Ltd. Class H is scheduled to report earnings on August 26, 2026, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Jun 25Dec 23Dec 22Dec 21
Income Statement
Total RevenueHK$ 37.12MHK$ 77.92MHK$ 73.75MHK$ 37.38MHK$ 106.74M
Gross ProfitHK$ 34.22MHK$ 62.49MHK$ 51.83MHK$ 27.20MHK$ 100.48M
Operating IncomeHK$ -151.39MHK$ -184.38MHK$ -241.26MHK$ -227.94MHK$ -411.45M
EBITDAHK$ -139.87MHK$ -173.74MHK$ -198.08MHK$ -170.77MHK$ -429.76M
Net IncomeHK$ -142.54MHK$ -155.89MHK$ -209.90MHK$ -182.81MHK$ -417.79M
Balance Sheet
Cash & Short-Term InvestmentsHK$ 508.15MHK$ 609.16MHK$ 637.54MHK$ 830.57MHK$ 1.21B
Total AssetsHK$ 861.37MHK$ 971.51MHK$ 854.83MHK$ 1.06BHK$ 1.45B
Total DebtHK$ 2.20MHK$ 1.26MHK$ 995.01KHK$ 2.17MHK$ 1.72M
Net DebtHK$ -505.96MHK$ -495.15MHK$ -41.16MHK$ -66.29MHK$ -401.47M
Total LiabilitiesHK$ 120.36MHK$ 130.31MHK$ 54.44MHK$ 66.53MHK$ 30.34M
Stockholders' EquityHK$ 741.01MHK$ 841.20MHK$ 800.40MHK$ 988.49MHK$ 1.42B
Cash Flow
Free Cash FlowHK$ -174.59MHK$ -163.18MHK$ -197.69MHK$ -127.69MHK$ -134.93M
Operating Cash FlowHK$ -168.56MHK$ -119.77MHK$ -166.88MHK$ -90.47MHK$ -118.32M
Investing Cash FlowHK$ 99.59MHK$ 56.88MHK$ 145.30MHK$ -167.18MHK$ 192.93M
Financing Cash FlowHK$ -1.39MHK$ 221.38MHK$ -1.25MHK$ 4.02MHK$ -1.21M
Currency in HKD

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Earnings and Revenue History

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Debt to Assets

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Cash Flow

Beijing Biostar Pharmaceuticals Co., Ltd. Class H Forecast EPS vs Actual EPS